
    
      Study duration per participant is approximately 13 months including 6-Month factor or BPA
      prophylaxis period and 7-Month fitusiran treatment period. Study duration for patients in the
      subgroup of Cohort A is approximately 7 months corresponding to a 7-Month fitusiran treatment
      period.

      Participants completing the treatment period will be proposed to enroll in an extension study
    
  